测定糖尿病患者血清LDL-C 水平的方法学比较

目的:比较不同方法检测糖尿病患者血清LDL-C水平,为临床诊疗提供准确可行的检验方法。方法:采用沉淀法、匀相法、电泳法及超速离心法对233例糖尿病患者和102例健康人群的血清LDL-C水平进行测定,比较各方法之间的相关性,同时分析导致结果差异的因素。结果:四种方法检测健康人群LDL-C水平,结果间无统计学差异(P>0.05);糖尿病组,当TG≤2.26mmol/L时,四种方法检测LDL-C结果间相关性良好。高胆红素、血红蛋白、高TG及乳糜等干扰因素存在时,与其他方法相比,电泳法和超速离心法检测血清LDL-C结果受影响较小(P>0.05)。结论:超速离心法虽耗时、价格贵,但仍为检测LDL-C的经典方法,电泳法受高胆红素、血红蛋白、高三酰甘油等干扰因素的影响相对较小,适用于糖尿病合并高血脂患者血清LDL-C水平检测。     

测定糖尿病患者血清LDL-C水平的方法学比较

目的：比较不同方法检测糖尿病患者血清LDL-C水平,为临床诊疗提供准确可行的检验方法。方法：采用沉淀法、匀相法、电泳法及超速离心法对233例糖尿病患者和102例健康人群的血清LDL-C水平进行测定,比较各方法之间的相关性,同时分析导致结果差异的因素。结果：四种方法检测健康人群LDL-C水平,结果间无统计学差异（P〉0.05）;糖尿病组,当TG≤2.26mmol/L时,四种方法检测LDL-C结果间相关性良好。高胆红素、血红蛋白、高TG及乳糜等干扰因素存在时,与其他方法相比,电泳法和超速离心法检测血清LDL-C结果受影响较小（P〉0.05）。结论：超速离心法虽耗时、价格贵,但仍为检测LDL-C的经典方法,电泳法受高胆红素、血红蛋白、高三酰甘油等干扰因素的影响相对较小,适用于糖尿病合并高血脂患者血清LDL-C水平检测。     

冠心病患者的血脂、胆红素、UA及Fib水平变化及临床意义

目的:研究冠心病(CHD)患者的血脂、胆红素、血尿酸(UA)及纤维蛋白原(Fib)水平变化及临床意义。方法:选取2014年4月到2015年4月我院收治的CHD患者110例(研究组),另选取同期健康体检者110例(对照组),检测两组受检者血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、直接胆红素(DBIL)、间接胆红素(IBIL)、总胆固醇(TBIL)、UA以及Fib水平。结果:研究组TC、TG、LDL-C、UA以及Fib水平均显著高于对照组,两组比较差异具有统计学意义(P0.05);研究组HDL-C、DBIL、IBIL以及TBIL均显著低于对照组,两组比较差异具有统计学意义(P0.05)。结论:血脂水平异常,胆红素水平降低,UA以及Fib水平增高与CHD的发病有关。     

女性冠心病患者胆红素血脂综合指数、ApoB水平与冠状动脉病变程度的相关性研究

目的:研究女性冠心病患者胆红素血脂综合指数、ApoB水平与冠脉病变程度的关系。方法:选取2016年1月-2016年12月于我院行冠状动脉造影检查的女性患者共246例,按照两种不同方法分组:(1)按照冠状动脉造影结果分为冠心病组(n=105)和正常对照组(n=141);(2)按照Gensini评分系统定量评估所有冠心病患者的冠状动脉病变程度,分为第1四分位组(n=35)、第2四分位组(n=32)、第3四分位组(n=39)及第4四分位组(n=35)。测定所有患者的血清总胆红素(TBIL)、直接胆红素(DBIL)、间接胆红素(IBIL)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、载脂蛋白A/B(ApoA/B)水平,计算胆红素血脂综合指数[TC/(HDL-C+TBIL)、LDL-C/(HDL-C+TBIL)]。结果:(1)冠心病组TC、TG、LDL-C、ApoB较正常组高,HDL-C、ApoA、TBIL、DBIL、IBIL较正常组低,差异有统计学意义(P0.05);与正常组相比,冠心病组胆红素血脂综合指数[TC/(HDL-C+TBIL)、LDL-C/(HDL-C+TBIL)]升高,差异有统计学意义(P0.05)。(2)在不同Gensini评分四分位组中,TC、LDL-C、ApoB、TBIL、DBIL、IBIL、TC/(HDL-C+TBIL)、LDL-C/(HDL-C+TBIL)的差异均有统计学意义(P0.05)。(3)相关性分析显示:TC/(HDL-C+TBIL)、LDL-C/(HDL-C+TBIL)、ApoB均与冠脉不同Gensini评分呈正相关(r=0.538,P0.05;r=0.670,P0.05;r=0.462,P0.05);TBIL、DBIL、IBIL与冠脉不同Gensini评分呈负相关(r=-0.485,P0.05;r=-0.564,P0.05;r=-0.359,P0.05)。结论:(1)女性冠心病患者血脂胆红素综合指数、ApoB较正常对照组患者显著升高,而TBIL、DBIL、IBIL降低;(2)女性冠心病患者胆红素血脂综合指数、ApoB水平与其冠脉病变程度呈显著正相关。     

中西医结合治疗对T2DM合并CHD患者血糖、血脂及血管内皮功能的影响

目的:探讨中西医结合治疗对2型糖尿病(T2DM)合并冠心病(CHD)患者血糖、血脂及血管内皮功能的影响。方法:将120例T2DM合并CHD患者上随机分为研究组与对照组各60例,在原饮食、运动疗法及降压、降糖治疗方案不变的条件下,对照组加用阿托伐他汀钙片治疗,研究组加用阿托伐他汀钙片与降脂通脉胶囊治疗。检测和比较两组治疗前后总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、空腹血糖(FBG)、餐后2h血糖(2h PBG)、一氧化氮(NO)及内皮素(CE)-1水平的变化。结果:两组治疗后FBG、2h PBG水平均较治疗前明显下降(P0.05),而组间比较差异无统计学意义(P0.05)。两组治疗后TG、TC、LDL-C水平均较治疗前明显下降(P0.05),HDL-C水平均较治疗前明显升高(P0.05),且研究组TG、TC、LDL-C水平显著低于对照组(P0.05),HDL-C水平显著高于对照组(P0.05)。两组治疗后血清NO水平均较治疗前明显升高(P0.05),血清CE水平均较治疗前明显下降(P0.05),且研究组血清NO水平明显高于对照组(P0.05),血清CE水平明显低于对照组(P0.05)。两组治疗过程中均未见明显不良反应。结论:降脂通脉胶囊联合阿托伐他汀可显著改善T2DM合并CHD患者的血脂和血管内皮功能,但不会进一步降低血糖。     

冠心病心力衰竭患者颈股搏波传导速度及血清BNP水平与冠状动脉病变程度的相关性研究

目的:探讨冠心病心力衰竭患者颈股搏波传导速度(cfPWV)及血清脑钠肽(BNP)水平与冠状动脉病变程度的相关性及其对患者预后的预测价值。方法:选择冠心病心力衰竭患者90例,依据心脏彩超EF值分别分为三组,A组(EF值>40%),B组(30%0.05)。C组的cfPWV明显快于A、B两组,存在显著性差异(P<0.05),A、B组间无统计学差异(P>0.05)。三组间收缩压、Gensini积分和血清BNP水平比较存在统计学差异(P<0.05)。A、B组间脉压比较无统计学差异(P>0.05),C组与A组、B组脉压比较均存在统计学差异(P<0.05)。CfPWV与血清BNP水平、Gensini积分呈正相关。cfPWV对冠心病心力衰竭患者预后的ROC曲线下面积为0.617,其预测冠心病心力衰竭患者发生不良事件的灵敏度为81.8%,特异性为60.9%;血清BNP水平对冠心病心力衰竭患者预后的ROC曲线下面积为0.767,其预测冠心病心力衰竭患者发生不良事件的灵敏度为93.2%,特异性为56.5%。结论:cfPWV与血清BNP水平、冠状动脉病变程度之间具有相关性,cfPWV对冠心病心力衰竭患者发生不良事件具有中等的预测价值,但其敏感性及特异性有限。     

血清ApoB/ApoA1比值、TG/HDL-C比值、LDH及ALP水平与冠心病患者冠状动脉病变严重程度的关系及其预测价值分析

摘要 目的：探讨血清载脂蛋白B（ApoB）/载脂蛋白A1（ApoA1）比值、三酰甘油（TG）/高密度脂蛋白胆固醇（HDL-C）比值、乳酸脱氢酶（LDH）及碱性磷酸酶（ALP）水平与冠心病（CHD）患者冠状动脉病变严重程度的关系及其预测价值。方法：选取2019年1月-2021年12月因胸痛来我院检查并收治的185例患者,根据检查结果是否为CHD分为CHD组（120例）和对照组（65例）,根据Gensini评分将CHD组分为轻度狭窄亚组36例、中度狭窄亚组55例、重度狭窄亚组29例。入院后检测血清ApoB/ApoA1比值、TG/HDL-C比值、LDH及ALP水平。采用Spearman相关系数分析CHD患者血清ApoB/ApoA1比值、TG/HDL-C比值、LDH、ALP水平与Gensini评分的相关性,采用多因素Logistic回归分析CHD的影响因素;受试者工作特征（ROC）曲线分析血清ApoB/ApoA1比值、TG/HDL-C比值、LDH及ALP水平对CHD的预测价值。结果：与对照组比较,CHD组吸烟、饮酒、高血压、糖尿病比例和血清总胆固醇（TC）、TG、低密度脂蛋白胆固醇（LDL-C）、ApoB、ApoB/ApoA1比值、TG/HDL-C比值、LDH、ALP水平升高,HDL-C、ApoA1水平降低（P＜0.05）。轻度、中度、重度狭窄亚组血清ApoB/ApoA1比值、TG/HDL-C比值、LDH及ALP水平依次升高（P＜0.05）。CHD患者血清ApoB/ApoA1比值、TG/HDL-C比值、LDH、ALP水平与Gensini评分呈正相关（P均＜0.001）。多因素Logistic回归分析显示,高血压、血清ApoB/ApoA1比值、TG/HDL-C比值、LDH、ALP水平升高为CHD的独立危险因素（P＜0.05）。ROC曲线分析显示,血清ApoB/ApoA1比值、TG/HDL-C比值、LDH及ALP水平联合预测CHD的曲线下面积大于单独预测（P＜0.05）。结论：血清ApoB/ApoA1比值、TG/HDL-C比值、LDH、ALP水平与CHD患者冠状动脉病变严重程度有关,且联合预测CHD的价值较高。     

阻塞性黄疸患者总胆汁酸的表达及与血脂水平的关系研究

目的:探讨阻塞性黄疸(OJ)患者血清总胆汁酸(TBA)水平与血脂水平的关系。方法:选择2015年5月到2015年12月我院收治的70例OJ患者作为观察组,同期选择70例健康人员作为对照组。检测并比较两组血清TBA、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、载脂蛋白AI(Apo AI)、载脂蛋白B(Apo B)、脂蛋白α[Lp(α)]、总胆红素(T-Bil)及直接胆红素(D-Bil)水平,并分析血清TBA与血脂水平的关系。结果:观察组患者的血清TBA、TG、TC、Apo B、T-Bil及D-Bil水平均明显低于对照组,血清LDL-C、HDL-C、Apo AI及Lp(α)水平均明显高于对照组,差异均具有统计学意义(P0.05)。Pearson直线相关性分析结果表明,血清TBA水平与血清TG、TC、Apo B、T-Bil及D-Bil呈正相关性,与血清LDL-C、HDL-C、Apo AI及Lp(α)水平呈负相关性。结论:OJ患者体内存在血脂水平紊乱,血清TBA可能是导致OJ患者血脂代谢紊乱的重要因素。     

不同剂量阿托伐他汀对稳定性心绞痛患者TNF-α 和LDL-C 水平的影响

目的:观察不同剂量阿托伐他汀对冠心病稳定性心绞痛患者血清肿瘤坏死因子a(TNF-α)和低密度脂蛋白胆固醇(LDL-C)水平的影响。方法:用酶联免疫吸附法和生化发光分析法测定40例正常对照组和40例阿托伐他汀10mg组及39例阿托伐他汀20mg组冠心病患者治疗前后血清TNF-α和LDL-C水平的变化。结果:阿托伐他汀10mg及20mg组患者治疗12周后血清TNF-α和LDL-C水平明显降低,并且阿托伐他汀20mg组比阿托伐他汀10mg组血清TNF-α下降更明显,差异有显著性(P<0.05),但两组间LDL-C水平降低无显著性差异(P>0.05)。结论:阿托伐他汀可以降低冠心病患者血清LDL-C和TNF-α水平,减轻冠心病的炎症反应,并且这种机制独立于降脂作用以外。     

匹伐他汀钙与阿托伐他汀钙治疗冠心病的临床疗效及安全性比较

目的:观察和比较匹伐他汀钙与阿托伐他汀钙治疗冠心病的临床疗效及安全性。方法:选取2016年3月到2018年12月于我院就诊的冠心病患者共100例,将其按照入院编号随机分为两组,匹伐他汀钙组(50例)与阿托伐他汀钙组(50例)。在服药前及服药后第6、12个月,检测和比较两组血糖(Glu)、糖化血红蛋白(HbA1c)、超敏C反应蛋白(hsCRP)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、谷丙转苷酶(ALT)、谷草转氨酶(AST)、肌酐(Cr)、肌酸激酶(CK)水平的变化。结果:治疗后6、12个月,匹伐他汀钙组血清HDL-C水平较治疗前显著升高(P0.05),而血清hsCRP水平明显降低(P0.05),阿托伐他汀钙组HDL-C、hsCRP与治疗前比较差异均没有统计学意义(P0.05)。治疗后12个月,阿托伐他汀钙组HbA1c较治疗前显著升高(P0.05),而匹伐他汀钙组与治疗前比较差异没有统计学意义(P0.05)。治疗后6、12个月,两组患者血清TC、LDL-C水平均较治疗前明显降低(P0.05),两组患者血清TG、Glu、ALT、AST、Cr、CK水平较治疗前差异无明显统计学意义(P0.05)。结论:匹伐他汀钙和阿托伐他汀钙治疗均能够降低冠心病患者的血清LDL-C、TC、TG水平,而匹伐他汀钙同时可升高HDL-C,降低血清hs CRP水平,并且不增加新发糖尿病的风险。     

Scurvy in capybaras bred in captivity in Argentine

In order to determine if the absence of vitamin C in the diet of capybaras (Hydrochoerus hydrochaeris) causes scurvy, a group of seven young individuals were fed food pellets without ascorbic acid, while another group of eight individuals received the same food with 1 g of ascorbic acid per animal per day. Animals in the first group developed signs of scurvy-like gingivitis, breaking of the incisors and death of one animal. Clinical signs appeared between 25 and 104 days from the beginning of the trial in all individuals. Growth rates of individuals deprived of vitamin C was considerably less than those observed in the control group. Deficiency of ascorbic acid had a severe effect on reproduction of another population of captive capybaras. We found that the decrease in ascorbic acid content in the diet affected pregnancy, especially during the first stages. The results obtained suggest that it is necessary to supply a suitable quantity of vitamin C in the diet of this species in captivity.     

Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures

Defects in mitochondrial energy metabolism have been implicated in the pathology of several neurodegenerative disorders. In addition, the reactive metabolites generated from the metabolism and oxidation of the neurotransmitter dopamine (DA) are thought to contribute to the damage to neurons of the basal ganglia. We have previously demonstrated that infusions of the metabolic inhibitor malonate into the striata of mice or rats produce degeneration of DA nerve terminals. In the present studies, we demonstrate that an intrastriatal infusion of malonate induces a substantial increase in DA efflux in awake, behaving mice as measured by in vivo microdialysis. Furthermore, pretreatment of mice with tetrabenazine (TBZ) or the TBZ analogue Ro 4-1284 (Ro-4), compounds that reversibly inhibit the vesicular storage of DA, attenuates the malonate-induced DA efflux as well as the damage to DA nerve terminals. Consistent with these findings, the damage to both DA and GABA neurons in mesencephalic cultures by malonate exposure was attenuated by pretreatment with TBZ or Ro-4. Treatment with these compounds did not affect the formation of free radicals or the inhibition of oxidative phosphorylation resulting from malonate exposure alone. Our data suggest that DA plays an important role in the neurotoxicity produced by malonate. These findings provide direct evidence that inhibition of succinate dehydrogenase causes an increase in extracellular DA levels and indicate that bioenergetic defects may contribute to the pathogenesis of chronic neurodegenerative diseases through a mechanism involving DA.     

Changes in lactate dehydrogenase activity in chicken tissues in hyperthyreosis in ontogenesis

The lactate dehydrogenase activity in reactions of lactate oxidation and synthesis was studied in subfractions of the chicken brain, heart and liver at the embryonal, early postembryonal and adult stages of development after thyroxine administration. It has been shown that during embryogenesis thyroxine predominantly enhanced the rate of lactate oxidation in the mitochondrial tissues. A marked increase in the lactate synthesis was found in cytoplasm of the adult chicken tissues. Specificity of enzyme activity alterations was detected in the chicken brain during ontogenesis after thyroxine administration.     

SSTR5 ablation in islet results in alterations in glucose homeostasis in mice

Somatostatin (SST) peptide is a potent inhibitor of insulin secretion and its effect is mediated via somatostatin receptor 5 (SSTR5) in the endocrine pancreas. To investigate the consequences of gene ablation of SSTR5 in the mouse pancreas, we have generated a mouse model in which the SSTR5 gene was specifically knocked down in the pancreatic beta cells (betaSSTR5Kd) using the Cre-lox system. Immunohistochemistry analysis showed that SSTR5 gene expression was absent in beta cells at three months of age. At the time of gene ablation, betaSSTR5Kd mice demonstrated glucose intolerance with lack of insulin response and significantly reduced serum insulin levels. Insulin tolerance test demonstrated a significant increase of insulin clearance in vivo at the same age. In vitro studies demonstrated an absence of response to SST-28 stimulation in the betaSSTR5Kd mouse islet, which was associated with a significantly reduced SST expression level in betaSSTR5Kd mice pancreata. In addition, betaSSTR5Kd mice had significantly reduced serum glucose levels and increased serum insulin levels at 12 months of age. Glucose tolerance test at an older age also indicated a persistently higher insulin level in betaSSTR5Kd mice. Further studies of betaSSTR5Kd mice had revealed elevated serum C-peptide levels at both 3 and 12 months of age, suggesting that these mice are capable of producing and releasing insulin to the periphery. These results support the hypothesis that SSTR5 plays a pivotal role in the regulation of insulin secretion in the mouse pancreas.